Invesco Ltd. Has $223,000 Holdings in C4 Therapeutics, Inc. $CCCC

Invesco Ltd. grew its holdings in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) by 101.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 139,486 shares of the company’s stock after purchasing an additional 70,293 shares during the period. Invesco Ltd. owned about 0.20% of C4 Therapeutics worth $223,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Jane Street Group LLC grew its position in shares of C4 Therapeutics by 49.4% during the 4th quarter. Jane Street Group LLC now owns 152,774 shares of the company’s stock worth $550,000 after purchasing an additional 50,523 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of C4 Therapeutics by 1,548.3% during the 4th quarter. Millennium Management LLC now owns 360,125 shares of the company’s stock worth $1,296,000 after acquiring an additional 338,277 shares during the period. SG Americas Securities LLC bought a new stake in shares of C4 Therapeutics during the 1st quarter worth approximately $680,000. Nuveen Asset Management LLC lifted its holdings in shares of C4 Therapeutics by 6.4% during the 4th quarter. Nuveen Asset Management LLC now owns 192,424 shares of the company’s stock worth $693,000 after acquiring an additional 11,571 shares during the period. Finally, ProShare Advisors LLC lifted its holdings in shares of C4 Therapeutics by 83.1% during the 4th quarter. ProShare Advisors LLC now owns 20,283 shares of the company’s stock worth $73,000 after acquiring an additional 9,204 shares during the period. Institutional investors and hedge funds own 78.81% of the company’s stock.

Analyst Ratings Changes

CCCC has been the subject of a number of recent analyst reports. Zacks Research downgraded shares of C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 22nd. Guggenheim initiated coverage on shares of C4 Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $8.00 price objective for the company. Finally, Wall Street Zen downgraded shares of C4 Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $8.00.

C4 Therapeutics Stock Performance

CCCC stock opened at $2.72 on Monday. The company has a fifty day moving average price of $2.25 and a 200-day moving average price of $1.88. The company has a market capitalization of $193.58 million, a P/E ratio of -1.72 and a beta of 2.98. C4 Therapeutics, Inc. has a 52-week low of $1.09 and a 52-week high of $7.22.

C4 Therapeutics (NASDAQ:CCCC) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.01. The firm had revenue of $6.46 million during the quarter, compared to the consensus estimate of $5.24 million. C4 Therapeutics had a negative net margin of 325.88% and a negative return on equity of 53.91%. As a group, sell-side analysts forecast that C4 Therapeutics, Inc. will post -1.52 earnings per share for the current fiscal year.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.